Chimeric antigen receptor targeting HLA-A, encoding gene, CAR-Tregs cells, and preparation method and application of CAR-Tregs cells

A chimeric antigen receptor and HLA-A technology, applied in the field of molecular genes, can solve the problems of increased risk of tumors and infections, and low specificity.

Active Publication Date: 2020-07-10
成都仕康美生物科技有限公司
View PDF12 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the use of immunosuppressants at this stage can effectively reduce the risk of rejection and improve the survival rate of grafts, because it reduces the overall immune function of the body, the specificity is not high, which leads to an increase in the risk of tumors, infections, etc.
At the same time, because immunosuppressants have certain drug toxicity, long-term use is likely to cause some chronic diseases, such as chronic kidney injury, hyperuricemia, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric antigen receptor targeting HLA-A, encoding gene, CAR-Tregs cells, and preparation method and application of CAR-Tregs cells
  • Chimeric antigen receptor targeting HLA-A, encoding gene, CAR-Tregs cells, and preparation method and application of CAR-Tregs cells
  • Chimeric antigen receptor targeting HLA-A, encoding gene, CAR-Tregs cells, and preparation method and application of CAR-Tregs cells

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0057] The present invention also provides a CAR-Tregs cell, and the CAR-Tregs cell is the Treg cell modified by the above-mentioned chimeric antigen receptor. The present invention also provides a method for preparing the above-mentioned CAR-Tregs cells, comprising: transfecting the chimeric antigen receptor into Treg cells for expression through its encoded nucleic acid sequence.

[0058] Preferably, the preparation method specifically includes:

[0059] (1) Construction of a chimeric antigen receptor lentiviral expression plasmid targeting HLA-A;

[0060] (2) Preparation of chimeric antigen receptor lentivirus targeting HLA-A;

[0061] (3) Transfect Treg cells with the chimeric antigen receptor lentivirus targeting HLA-A prepared in step (2).

[0062] The present invention provides the application of the above-mentioned CAR-Tregs cells in the preparation of drugs for treating or preventing transplant rejection and graft-versus-host disease, or in the preparation of drugs ...

Embodiment 1

[0065] 1. Construction of lentiviral expression plasmid

[0066] 1. Preparation of coding gene sequence of chimeric antigen receptor

[0067] Preparation of CD8 signal peptide, single-chain antibody targeting HLA-A11, CD8α hinge region, CD8 transmembrane region, 4-1BB hinge region, 4-1BB transmembrane region, 4-1BB intracellular signaling domain and CD3ζ signaling domain coding genes;

[0068] The single-chain antibody targeting HLA-A11 includes a tandem HLA-A11 single-chain antibody heavy chain VH, a connecting peptide, and an HLA-A11 single-chain antibody light chain VL; the HLA-A11 single-chain antibody heavy chain VH is located in the target HLA - the N-terminal of the single-chain antibody of A11, the light chain VL of the HLA-A11 single-chain antibody is located at the C-terminal of the single-chain antibody targeting the HLA-A11; the gene encoding the heavy chain VH of the HLA-A11 single-chain antibody is as shown in SEQ ID NO The nucleotide sequence shown in .1, the ...

Embodiment 2

[0118] The only difference between this example and Example 1 is that the HLA-A33-targeting single-chain antibody is used to replace the HLA-A11-targeting single-chain antibody, and finally HLA-A33-CAR-Tregs are obtained.

[0119] Wherein, the single-chain antibody targeting HLA-A33 includes a tandem HLA-A33 single-chain antibody heavy chain VH, a connecting peptide, and an HLA-A33 single-chain antibody light chain VL; the HLA-A33 single-chain antibody heavy chain VH is located at the target To the N-terminus of the single-chain antibody of HLA-A33, the light chain VL of the HLA-A33 single-chain antibody is located at the C-terminus of the single-chain antibody targeting the HLA-A33; the gene encoding the heavy chain VH of the HLA-A33 single-chain antibody is as shown in SEQ The nucleotide sequence shown in ID NO.3, the nucleotide sequence shown in SEQ ID NO.4 of the HLA-A33 single-chain antibody light chain VL coding gene; the connecting peptide coding gene is shown in SEQ ID ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a chimeric antigen receptor targeting HLA-A, an encoding gene, a recombinant expression vector, CAR-Tregs cells, and a preparation method and application of the CAR-Tregs cells. The chimeric antigen receptor comprises a signal peptide, an antigen binding domain, a hinge region, a transmembrane region, a co-stimulatory factor and an intracellular signal transduction domain;the antigen binding domain is a binding domain of an anti-HLA-A11 antibody or an anti-HLA-A33 antibody; the CAR-Tregs cells disclosed by the invention are Treg cells modified by the chimeric antigen receptor targeting HAL-A11 or HLA-A33, can inhibit specific immunoreaction and can be used for inhibition from solid organ transplantation postoperative rejection reaction.

Description

technical field [0001] The invention relates to the field of molecular gene technology, in particular to a chimeric antigen receptor targeting HLA-A, a coding gene, a recombinant expression vector, CAR-Tregs cells, a preparation method, and an application. Background technique [0002] There are approximately 300,000 solid organ transplant recipients in China, who face a huge risk of rejection after surgery. Although the use of immunosuppressants at this stage can effectively reduce the risk of rejection and improve the survival rate of grafts, because it reduces the overall immune function of the body and has low specificity, it leads to an increase in the risk of tumors and infections. At the same time, because immunosuppressants have certain drug toxicity, long-term use is likely to cause some chronic diseases, such as chronic kidney injury, hyperuricemia and so on. Contents of the invention [0003] In view of this, the present application provides a chimeric antigen ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K19/00C12N15/62C12N15/867C12N5/10A61K35/17A61P37/06
CPCA61K35/17A61P37/06C07K14/7051C07K16/2833C07K2317/622C07K2319/02C07K2319/03C07K2319/33C12N5/0637C12N15/86C12N2510/00C12N2740/15043
Inventor 魏亮
Owner 成都仕康美生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap